{"id":"placebo-and-triamcinolone-ointment","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Local irritation or burning"},{"rate":null,"effect":"Systemic corticosteroid absorption (with prolonged use)"}]},"_chembl":{"chemblId":"CHEMBL1200449","moleculeType":"Small molecule","molecularWeight":"478.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Triamcinolone acetonide is a synthetic glucocorticoid that binds to glucocorticoid receptors in the skin, suppressing the production of inflammatory cytokines and reducing vasodilation, edema, and immune cell infiltration. The placebo component serves as a control in this formulation. When applied topically as an ointment, it provides anti-inflammatory, antipruritic, and vasoconstrictive effects localized to the affected skin area.","oneSentence":"Triamcinolone is a topical corticosteroid that reduces inflammation and immune response in skin conditions by suppressing inflammatory mediators and immune cell activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:36.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic dermatological conditions (e.g., eczema, psoriasis, dermatitis)"}]},"trialDetails":[{"nctId":"NCT03568318","phase":"PHASE3","title":"A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-08-09","conditions":"Atopic Dermatitis","enrollment":1533},{"nctId":"NCT07131813","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2025-10-10","conditions":"Oral Lichen Planus","enrollment":60},{"nctId":"NCT02260986","phase":"PHASE3","title":"Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-09","conditions":"Atopic Dermatitis","enrollment":740},{"nctId":"NCT01544842","phase":"NA","title":"Tacrolimus Ointment in Oral Lichen Planus","status":"TERMINATED","sponsor":"University of Oulu","startDate":"2004-08","conditions":"Oral Lichen Planus","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo and Triamcinolone ointment","genericName":"Placebo and Triamcinolone ointment","companyName":"All India Institute of Medical Sciences, Bhubaneswar","companyId":"all-india-institute-of-medical-sciences-bhubaneswar","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triamcinolone is a topical corticosteroid that reduces inflammation and immune response in skin conditions by suppressing inflammatory mediators and immune cell activity. Used for Inflammatory and pruritic dermatological conditions (e.g., eczema, psoriasis, dermatitis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}